Welcome to our dedicated page for aTyr Pharma news (Ticker: LIFE), a resource for investors and traders seeking the latest updates and insights on aTyr Pharma stock.
aTyr Pharma, Inc. (NASDAQ: LIFE) is a clinical-stage biotechnology company pioneering protein therapeutics for rare immune-mediated diseases through its innovative physiocrine biology platform. This page serves as the definitive source for verified news and scientific developments related to the company's research programs, clinical trials, and intellectual property advancements.
Investors and researchers will find timely updates on key initiatives including progress for lead candidate resolaris™ in muscular dystrophy trials, regulatory milestones, and strategic collaborations. All content is curated to provide actionable insights while maintaining compliance with financial disclosure standards.
The repository includes press releases on clinical trial phases, peer-reviewed research publications, patent grants, and executive commentary. Content is organized chronologically to track the company's evolution in treating rare myopathies through novel protein modulation approaches.
Bookmark this page for direct access to primary source materials from aTyr Pharma, ensuring you remain informed about developments in this specialized area of rare disease therapeutics. Check regularly for updates reflecting the company's progress in translating physiocrine biology research into potential treatments.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced that the U.S. Patent and Trademark Office has granted a patent for methods using histidyl-tRNA synthetase Fc fusion proteins to reduce inflammatory responses in the lung. This patent pertains to ATYR1923, a candidate in clinical development for pulmonary sarcoidosis and other inflammatory lung diseases. The patent expands aTyr's intellectual property estate, which includes over 220 patents. Results from recent trials show that ATYR1923 may effectively lower inflammatory cytokine levels in patients.
aTyr Pharma (Nasdaq: LIFE) announced that the last patient in its Phase 1b/2a clinical trial of ATYR1923 for pulmonary sarcoidosis has completed their final visit. The trial, involving 37 patients, aims to assess the safety, tolerability, and preliminary efficacy of ATYR1923. Results are anticipated in September 2021. ATYR1923, a fusion protein targeting neuropilin-2, seeks to modulate immune responses in severe inflammatory lung diseases. This milestone is a significant step for aTyr and the sarcoidosis community.
aTyr Pharma, Inc. (Nasdaq: LIFE) will host a virtual Key Opinion Leader event on June 29, 2021, at 5:00 PM ET, featuring Dr. Daniel Culver from the Cleveland Clinic. The discussion will focus on treatment options for pulmonary sarcoidosis, addressing the unmet needs of patients and the challenges of long-term steroid use. aTyr’s lead candidate, ATYR1923, is under evaluation in a Phase 1b/2a study for its safety and efficacy, with data expected in Q3 2021. Attendees will also have the opportunity to engage in a live Q&A session.
aTyr Pharma announced the presentation of its preclinical candidate aNRP2-14 at the Antibody Engineering & Therapeutics Europe Virtual conference, which took place from June 8 to 10, 2021. This antibody selectively blocks Semaphorin 3F/NRP2 signaling pathways linked to immune-mediated diseases, demonstrating significant potential. The findings suggest that aNRP2-14 could serve a therapeutic role, expanding aTyr's pipeline targeting chronic inflammation. This follows the development of their lead candidate, ATYR2810, which is in preclinical trials for cancer.
aTyr Pharma (Nasdaq: LIFE) has appointed Dr. Sara Zaknoen to its Board of Directors. Dr. Zaknoen, with extensive experience in pharmaceutical drug development, previously served as Chief Medical Officer at several biotech firms. This strategic appointment comes as aTyr prepares for the readout of its proof-of-concept study for ATYR1923 in pulmonary sarcoidosis by Q3 2021. The company is also advancing its oncology candidate ATYR2810, targeting Neuropilin-2. Dr. Zaknoen's background is expected to enhance aTyr's clinical development efforts.
aTyr Pharma announced findings related to ATYR2810, a Neuropilin-2 (NRP2) antibody, presented at the Virtual Keystone Symposia on Cancer Stem Cells. The research demonstrates that ATYR2810 effectively blocks the NRP2/VEGF signaling axis, enhancing chemotherapy sensitivity in triple-negative breast cancer (TNBC) models. Notably, ATYR2810 downregulates cancer stem cell and epithelial-mesenchymal transition markers in TNBC samples. These findings underscore the potential of ATYR2810 as a therapeutic candidate in treating aggressive tumors.
aTyr Pharma reported Q1 2021 results, highlighting progress in its clinical trials and research initiatives. The company anticipates data from a Phase 1b/2a trial of ATYR1923 in pulmonary sarcoidosis by Q3 2021. Preclinical data for ATYR2810 showed anti-tumor effects in triple-negative breast cancer and non-small cell lung cancer. As of March 31, 2021, aTyr had $50.6 million in cash and equivalents. The company raised $25.2 million through offerings during Q1 2021 and expects ongoing increases in expenses due to heightened R&D activities.
aTyr Pharma (Nasdaq: LIFE) announced that its Hong Kong subsidiary, Pangu BioPharma, achieved key milestones in a two-year, $750,000 grant from the Hong Kong Government’s Innovation and Technology Commission. The project, in collaboration with the Hong Kong University of Science and Technology, focuses on developing bispecific antibodies targeting Neuropilin-2 (NRP2) for diseases like cancer. The initial year included establishing a research team and implementing a novel antibody discovery approach, yielding promising candidates for therapeutic assays.
aTyr Pharma, Inc. (Nasdaq: LIFE) announced the promotion of Leslie Nangle, Ph.D., to Vice President, Research, on May 11, 2021. Dr. Nangle has been with aTyr since 2007, previously serving as Senior Director and Head of Research. With over 20 years in tRNA synthetase research, she is well-positioned to lead ongoing projects, including the development of ATYR1923, aimed at treating inflammatory lung diseases. aTyr focuses on innovative medicines derived from novel biological pathways, boasting an IP portfolio of over 300 therapeutically relevant proteins.
aTyr Pharma (Nasdaq: LIFE) will report its first quarter 2021 financial results on May 13, 2021, after market close. The management will host a conference call and webcast at 5:00 pm EDT to discuss the results and provide a corporate update. The company specializes in innovative medicines based on biological pathways, focusing on ATYR1923, a candidate for inflammatory lung diseases. For more details, visit aTyr Pharma's website.
